Cytori Therapeutics (NASDAQ:CYTX) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report released on Wednesday.
According to Zacks, “Cytori Therapeutics, Inc. is discovering and developing proprietary cell-based therapeutics utilizing adult stem and regenerative cells derived from adipose tissue, also known as fat. The Company’s preclinical investigational therapies target cardiovascular disease, spine and orthopedic conditions, gastrointestinal disorders, and new approaches for aesthetic and reconstructive surgery. To facilitate processing and delivery of adipose stem and regenerative cells, Cytori has developed its proprietary Celution System to isolate and concentrate a patient’s own stem and regenerative cells in about an hour. This system will dramatically improve the speed in which personalized cell-based therapies can be delivered to patients. “
CYTX has been the topic of several other research reports. HC Wainwright set a $40.00 price objective on Cytori Therapeutics and gave the company a “buy” rating in a research report on Monday, May 14th. ValuEngine downgraded Cytori Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Monday, April 2nd. Finally, Maxim Group set a $20.00 price objective on Cytori Therapeutics and gave the company a “buy” rating in a research report on Wednesday, March 28th. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $13.75.
Cytori Therapeutics (NASDAQ:CYTX) last released its quarterly earnings results on Thursday, May 10th. The biotechnology company reported ($0.70) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.40) by ($0.30). Cytori Therapeutics had a negative net margin of 428.14% and a negative return on equity of 190.35%. The company had revenue of $0.73 million for the quarter, compared to analysts’ expectations of $2.43 million. During the same quarter in the previous year, the company posted ($2.40) EPS. analysts anticipate that Cytori Therapeutics will post -1.74 earnings per share for the current fiscal year.
About Cytori Therapeutics
Cytori Therapeutics, Inc, a therapeutics company, together with its subsidiaries, develops regenerative and oncologic therapies from its proprietary cell therapy and nanoparticle platforms for various medical conditions. Its lead drug candidate, ATI-0918, is a generic version of pegylated liposomal encapsulated doxorubicin, which is in Phase III clinical trial and used for various cancer types.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cytori Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytori Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.